CLBP Market

DelveInsight’s ‘Chronic Lower Back Pain (CLBP) Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the CLBP, historical and forecasted epidemiology as well as the CLBP market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

The CLBP market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM CLBP market size from 2019 to 2032. The Report also covers current CLBP treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Chronic Lower Back Pain (CLBP) Disease Understanding and Treatment Algorithm

CLBP Overview

Chronic low back pain (CLBP) is pain that persists for 12 weeks or longer, even after an initial injury or underlying cause of acute low back pain. Low back pain is widespread and likely to affect everyone at one point. The exact cause of lower back pain is not found yet. Lower back pain that is long-term (for more than 3 months) is called CLBP. This condition might originate from an injury, disease, or stress on different body structures. The pain may vary significantly and be felt as bone pain, nerve pain, or muscle pain, and its intensity ranges from mild to severe. CLBP is the second leading cause of disability worldwide, being a major welfare and economic problem. The prevalence of CLBP in adults has increased significantly in the last decade and is continuously increasing vividly in the aging population. This condition affects men and women in all ethnic groups equally. This disease also leads to stress, depression, and anxiety. CLBP has adverse physical and psychological repercussions. It creates a significant economic burden due to loss of function, loss of work productivity, treatment costs, and disability payments.

 

CLBP originates from different conditions and may start from diseases, injuries, or stress to many different anatomic structures, including bones, muscles, ligaments, joints, nerves, or the spinal cord. The affected structure sends a signal through nerve endings, up to the spinal cord and into the brain, where it registers as pain.

Several theories have been given to explain or find out the exact underlying cause of CLBP, but it is believed that the nerve pathways that carry the pain signals from the nerve endings through the spinal cord and to the brain may become sensitized. Sensitization of these pathways may increase the frequency or intensity of the signals with which pain is perceived. Sometimes when the condition has been treated, the sensitized pathway continues to send signals to the brain, which sometimes, with great intensity, causes immense pain and feels just as real as the pain caused by the original injury or disease.

Continued in the report…..

 

CLBP Diagnosis

CLBP is usually investigated by physician evaluation or by imaging studies. The primary goal of diagnosis is to characterize the pain as mechanical, primarily when history is obtained from a patient with CLBP and sciatica. Mechanical or activity-related spinal pain is most often aggravated by static loading of the spine (prolonged sitting or standing), long-lever activities (vacuuming or working with the arms elevated and away from the body), and levered postures (forward bending of the lumbar spine). Pain is reduced when multidirectional forces balance the spine (walking or constantly changing positions) and when the spine is unloaded. Patients with mechanical LBP often prefer to lie still in bed. In contrast, those with a vascular or visceral cause are often found writhing in pain, unable to find a comfortable position.

Continued in the report…..

 

CLBP Treatment

CLBP is the most prevalent chronic pain condition and the second most common cause of disability in the US, after arthritis or rheumatism. CLBP may be nociceptive or neuropathic or include both components. The presence of a neuropathic component is related to the more intense pain of longer duration and a higher prevalence of comorbidities. The actual mechanism and cause of CLBP are still unknown, and due to this situation, there are no universally accepted treatment guidelines, and the management of the treatment is limited. If the source of the pain is not known or cannot be treated, the best option remains is to reduce the flare-ups and to make the pain manageable with nonsurgical treatments. There are nonsurgical treatments (physical therapy, diet, meditation, and lifestyle modifications), injection-based treatments, and pharmacologic treatments.

Continued in the report…..

CLBP Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent population of CLBP, total diagnosed prevalent population of CLBP, gender-specific diagnosed prevalence of CLBP, and age-specific diagnosed prevalence of CLBP scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

 

Key Findings

  • In 2020, the total prevalent population of chronic lower back pain were found out to be  76,440,725 in the 7MM, these cases are expected to grow at a CAGR of 0.55% for the study period 2019–2020.
  • The estimates suggest the highest diagnosed prevalent cases of CLBP in the United States with 35,059,702 cases in 2020.
  • The total number of CLBP cases in females was the 17,291,445 and in males it was  14,262,287 cases in 2020, in the US.
  • The highest number of CLBP cases were in the age group 70+ years with 6,736,354 cases in the EU-5 and the least number of cases of CLBP were found in 18–29 years age group with 2,363,980 cases in 2020, in EU-5.
  • Japan had 10,826,931 diagnosed prevalent cases of CLBP in 2020.

Country-Wise CLBP Epidemiology

The epidemiology segment also provides the CLBP epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

CLBP Drug Chapters

CLBP Emerging Drugs

 

Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.

Brixadi (CAM2038/buprenorphine injection depot) is a novel, ready-to-use, long-acting, investigational buprenorphine weekly and monthly subcutaneous depot injection for flexible and individualized treatment of both moderate-to-severe opioid use disorder and moderate-to-severe chronic pain. The drug is a partial agonist at the mu-opioid receptor and exhibits antagonistic effects at the kappa opioid receptor.

 

Semdexa (SP-102): Scilex Holding

Semdexa (SP-102, dexamethasone sodium phosphate) is a nonopioid corticosteroid formulated as a viscous gel injection that is under development to treat lumbar radicular pain/sciatica, containing no neurotoxic preservatives, surfactants, solvents, or particulates. Because of these properties, the drug is expected to result in a better safety profile than commonly used off-label injected corticosteroids. SP-102 has an ingredient that is a widely used corticosteroid solution. Corticosteroids have been given epidurally (directly into the spine) for the pain caused by sciatica since about 1970; however, there is no US FDA–approved injectable corticosteroid for sciatica. SP-102 is a treatment intended to produce an anti‑inflammatory effect from the widely used corticosteroid solution, and it is intended to last longer than other steroid injections possibly used by your doctor to treat sciatica.

Products detail in the report…

List to be continued in the report…

CLBP Market Outlook

CLBP is a complex process and comparable to how each patient has a very individualized disease process the treatment regimen is similarly individualized. There are several different medication classes, each with an exclusive mechanism of action that can help the practitioner in targeting a specific aspect of a patient's pain. Moreover, patient‐specific factors are taken into account when developing a regimen to ensure adherence and improve outcomes.

 

Prior to initiating any pharmacologic treatment regimen for a patient, current consensus recommendations include discussing realistic expectations with the patient. This includes the expectation of a patient in terms of pain relief as well as functional goals that the patient should work toward. Additionally, clinicians encourage self‐care and education with evidence‐based materials.

Continued in the report…..

 

Key Findings

  • The CLBP market size in the 7MM is expected to rise from USD 6,227 million in 2020 at a CAGR of 3.85% for the study period (2019–2032).
  • The United States accounted for the highest market size of CLBP, in comparison to the other major markets i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan in 2020.
  • Among the EU5 countries, Spain had the highest CLBP market size with USD 317 million in 2020, while Italy had the lowest market size of CLBP with USD 94 million in 2020.

 

The United States CLBP Market Outlook

This section provides the total CLBP market size and; market size by therapies in the United States.

 

EU-5 CLBP Market Outlook

The total CLBP market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan CLBP Market Outlook

The total CLBP market size and market size by therapies in Japan are provided.

CLBP Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the CLBP market or expected to get launched in the market during the study period 2019–2032. The analysis covers the CLBP market uptake by drugs; patient uptake by therapies; and sales of each drug.  

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

CLBP Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for CLBP emerging therapies.

Reimbursement Scenario in chronic lower back pain

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the CLBP market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 

Scope of the Report

  • The report covers the descriptive overview of CLBP, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the CLBP epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for CLBP is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the CLBP market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM CLBP market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA, increasing incidence, effectiveness of drugs as both mono and combination therapy will positively drive the CLBP market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence chronic lower back pain R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for CLBP. The launch of emerging therapies will significantly impact the CLBP market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

CLBP Report Insights

  • CLBP Patient Population
  • Therapeutic Approaches
  • CLBP Pipeline Analysis
  • CLBP Market Size
  • CLBP Market Trends
  • CLBP Market Opportunities
  • Impact of upcoming Therapies

CLBP Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • CLBP Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed CLBP Market
  • CLBP Drugs Uptake

CLBP Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • CLBP Market Attractiveness
  • CLBP Market Drivers
  • CLBP Market Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the CLBP market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the CLBP total market size as well as market size by therapies across the 7MM during the forecast period (2021–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest CLBP market size during the forecast period (2021–2032)?
  • At what CAGR, the CLBP market is expected to grow at the 7MM level during the forecast period (2021–2032)?
  • What would be the CLBP market outlook across the 7MM during the forecast period (2021–2032)?
  • What would be the CLBP market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of CLBP?
  • What is the historical CLBP patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of CLBP at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CLBP?
  • Out of the above-mentioned countries, which country would have the highest incident population of CLBP during the forecast period (2021–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of CLBP along with the approved therapy?
  • What are the current treatment guidelines for the treatment of CLBP in the US and Europe?
  • What are the CLBP marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of CLBP?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of CLBP?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CLBP therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for CLBP and their status?
  • What are the key designations that have been granted for the emerging therapies for CLBP?
  • What are the 7MM historical and forecasted market of CLBP?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving CLBP.
  • To understand the future market competition in the CLBP market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for CLBP in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the CLBP market.
  • To understand the future market competition in the CLBP market.

1. Key Insights

2. Report Introduction

3. Chronic Lower Back Pain Market Overview at a Glance

3.1. Market Share (%) of Chronic Lower Back Pain by Therapies in 2019

3.2. Market Share (%) of Chronic Lower Back Pain by Therapies in 2032

4. Executive Summary of Chronic lower back pain (CLBP)

5. Key Events

6. Chronic Lower Back Pain (CLBP): Disease Background and Overview

6.1. Introduction

6.2. Signs and Symptoms

6.3. Causes and Risk Factors

6.4. Genetics of Chronic Lower Back Pain

6.5. Pathophysiology

6.6. Types of pain

6.7. Diagnosis

6.7.1. Test for CLAB diagnosis

6.7.2. Imaging guidelines

6.8. Treatment and Management

6.8.1. Treatment Approaches

6.8.2. Treatment Algorithm

6.8.3. Proposed Guidelines for Chronic Lower Back Pain

6.8.3.1. NICE Guidelines

6.8.3.2. Center for Disease Control and Prevention (CDC) Guidelines

6.8.3.3. American College of Physicians (ACP) Guidelines

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Methodology

7.3. Total Prevalent Cases of Chronic Lower Back Pain in the 7MM

7.4. Diagnosed Prevalent Cases of Chronic Lower Back Pain in the 7MM

7.5. The United States

7.5.1. Assumptions and Rationale

7.5.2. Total Prevalent Population of Chronic Lower Back Pain in the United States

7.5.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States

7.5.4. Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States

7.5.5. Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States

7.6. EU5

7.6.1. Assumptions and Rationale

7.6.2. Total Prevalent Population of Chronic Lower Back Pain in EU-5

7.6.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in EU-5

7.6.4. Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5

7.6.5. Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5

7.7. Japan

7.7.1. Assumptions and Rationale

7.7.2. Total Prevalent Population of Chronic Lower Back Pain in Japan

7.7.3. Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan

7.7.4. Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan

7.7.5. Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan

8. Patient Journey

9. CLBP Marketed Therapies

9.1. Key Cross Competition

9.2. Cymbalta (Duloxetine): Eli Lilly and Company

9.2.1. Product Description

9.2.2. Regulatory Milestones

9.2.3. Other Developmental Activities

9.2.4. Clinical development

9.2.5. Clinical Trials Information

9.2.6. Safety and Efficacy

9.2.7. Product Profile

9.3. Xtampza: Collegium Pharmaceutical

9.3.1. Product Description

9.3.2. Regulatory Milestones

9.3.3. Other Developmental Activities

9.3.4. Clinical Development

9.3.5. Clinical trial information

9.3.6. Safety and Efficacy

9.3.7. Product Profile

9.4. Hysingla ER: Purdue Pharma LP

9.4.1. Product Description

9.4.2. Regulatory Milestones

9.4.3. Other Developmental Activities

9.4.4. Clinical Development

9.4.5. Clinical trial information

9.4.6. Safety and Efficacy

9.4.7. Product Profile

9.5. Butrans (buprenorphine): Purdue Pharma

9.5.1. Product Description

9.5.2. Regulatory Milestones

9.5.3. Clinical Development

9.5.4. Clinical Trials Information

9.5.5. Safety and Efficacy

9.5.6. Product Profile

9.6. Belbuca: BioDelivery Sciences International

9.6.1. Product Description

9.6.2. Regulatory Milestones

9.6.3. Other Developmental activities

9.6.4. Clinical Development

9.6.5. Clinical Trials Information

9.6.6. Safety and Efficacy

9.6.7. Product Profile

10. Emerging Therapies

10.1. Key Cross Competition

10.2. Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot): Camurus/Braeburn Inc.

10.2.1. Drug Description

10.2.2. Other Developmental Activities

10.2.3. Clinical Development

10.2.4. Clinical Trials Information

10.2.5. Safety and Efficacy

10.2.6. Product Profile

10.2.7. Analysts’ Views

10.3. Semdexa (SP-102): Scilex Holding

10.3.1. Product Description

10.3.2. Other Developmental Activities

10.3.3. Clinical Development

10.3.4. Clinical Trials Information

10.3.5. Safety and Efficacy

10.3.6. Product Profile

10.3.7. Analysts’ Views

10.4. Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited

10.4.1. Drug Description

10.4.2. Other Developmental Activities

10.4.3. Clinical Development

10.4.4. Clinical Trials Information

10.4.5. Safety and Efficacy

10.4.6. Product Profile

10.4.7. Analysts’ Views

10.5. AMG0103: AnGes MG, Inc.

10.5.1. Drug Description

10.5.2. Clinical Development

10.5.3. Clinical Trials Information

10.5.4. Safety and Efficacy

10.5.5. Product Profile

10.5.6. Analysts’ Views

10.6. KLS-2031: Kolon Life Science

10.6.1. Drug Description

10.6.2. Other Developmental Activities

10.6.3. Clinical Development

10.6.4. Clinical Trials Information

10.6.5. Product Profile

10.6.6. Analysts’ Views

10.7. ETX-810: Eliem Therapeutics

10.7.1. Drug Description

10.7.2. Other Developmental Activities

10.7.3. Clinical Development

10.7.4. Clinical Trials Information

10.7.5. Product Profile

10.7.6. Analysts’ Views

10.8. ALLOD-2: Allodynic Therapeutics

10.8.1. Product Description

10.8.2. Other Developmental Activities

10.8.3. Clinical Development

10.8.4. Clinical Trials Information

10.8.5. Product Profile

10.9. FB3001: Frontier Biotechnologies

10.9.1. Drug Description

10.9.2. Other Developmental Activities

10.9.3. Clinical Development

10.9.4. Clinical Trial Information

10.9.5. Safety and efficacy

10.9.6. Product profile

10.10. IDCT (rebonuputemcel): DiscGenics Inc.

10.10.1. Drug Description

10.10.2. Other Developmental Activities

10.10.3. Clinical Developmental Activities

10.10.4. Clinical trial information

10.10.5. Safety and efficacy

10.10.6. Product Profile

10.10.7. Analysts’ Views

10.11. SX600: SpineThera

10.11.1. Product Description

10.11.2. Other Developmental Activities

10.11.3. Clinical Development

10.11.4. Clinical Trials Information

10.11.5. Product Profile

10.12. STA363: Stayble Therapeutics

10.12.1. Product Description

10.12.2. Other Developmental Activities

10.12.3. Clinical Development

10.12.4. Clinical Trials Information

10.12.5. Product Profile

10.13. Clonidine Micropellets (STX-015): Sollis Therapeutics/Medtronic Spinal and Biologics

10.13.1. Product Description

10.13.2. Other Development Activities

10.13.3. Clinical development

10.13.4. Clinical Trials Information

10.13.5. Safety and Efficacy

10.13.6. Product Profile

10.14. Tanezumab: Eli Lilly/Pfizer

10.14.1. Product Description

10.14.2. Other Developmental Activities

10.14.3. Clinical Development

10.14.4. Clinical Trials Information

10.14.5. Safety and Efficacy

10.14.6. Product Profile

10.14.7. Analysts’ Views

10.15. LY3556050: Eli Lilly and Company

10.15.1. Drug Description

10.15.2. Clinical Development

10.15.3. Clinical Trials Information

10.15.4. Product Profile

10.16. PP353: Persica Pharmaceuticals

10.16.1. Drug Description

10.16.2. Other Developmental Activities

10.16.3. Clinical Development

10.16.4. Clinical Trials Information

10.16.5. Product Profile

10.17. BRTX-100: BioRestorative Therapies

10.17.1. Drug Description

10.17.2. Other Developmental Activities

10.17.3. Clinical Development

10.17.4. Clinical Trials Information

10.17.5. Product Profile

10.17.6. Analysts’ Views

10.18. VER-01: Vertanical GmbH

10.18.1. Drug Description

10.18.2. Clinical Development

10.18.3. Clinical Trials Information

10.18.4. Product Profile

10.19. BM-MSC/ReSpine: Montpellier University Hospital

10.19.1. Product Description

10.19.2. Clinical development

10.19.3. Clinical Trials Information

10.19.4. Product Profile

11. Failed therapies

11.1. Fasinumab (REGN475): Regeneron Pharmaceuticals/Teva Pharmaceuticals

11.1.1. Product Description

11.1.2. Other Developmental Activities

11.1.3. Clinical Development

11.1.4. Clinical Trials Information

11.1.5. Safety and Efficacy

11.1.6. Product Profile

12. Chronic Lower Back Pain: Seven Major Market Analysis

12.1. Key Findings

12.2. Market Methodology

12.3. CLBP Market Outlook

12.3.1. United States

12.3.2. EU-5 countries

12.3.3. Japan CLBP Market

12.4. Attribute Analysis

12.5. Potential of Emerging Therapies of Chronic Low Back Pain

12.6. Key Market Forecast Assumptions

12.7. Market size of Chronic Lower Back Pain in the 7MM

12.8. Market size of Chronic Lower Back Pain by Therapies in the 7MM

12.9. Market size of Chronic Lower Back Pain in the United States

12.9.1. Total Market size of Chronic Lower Back Pain in the United States

12.9.2. Market Size by Therapies in the US

12.10. Market size of Chronic Lower Back Pain in EU-5

12.10.1. Total Market size of Chronic Lower Back Pain in EU5

12.10.2. Market Size of Chronic Lower Back Pain in EU5 by Therapies

12.11. Market size of Chronic Lower Back Pain in Japan

12.11.1. Total Market size of Chronic Lower Back Pain

12.11.2. Market Size by Therapies in Japan

13. KOL Views

14. CLBP Market Drivers

15. CLBP Market Barriers

16. SWOT Analysis

17. Unmet Needs

18. CLBP Market Access and Reimbursement

19. Appendix

19.1. Report Methodology

19.2. Bibliography

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Table

Table 1: Summary of CLBP Market and Epidemiology (2019–2032)

Table 2: Key Events

Table 3: Risk Factors for Occurrence and Chronicity of Low Back Pain

Table 4: Cause of Muscle Connective Tissue Fibrosis

Table 5: Clinical Evaluation

Table 6: Graded Chronic Pain Scale (GCPS)

Table 7: Summary of the Efficacy of Physical Treatments for Chronic LBP

Table 8: The American College of Physicians Guideline Grading System

Table 9: Clinical Practice Guideline From the American College of Physicians

Table 10: Total Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019–2032)

Table 11: Diagnosed Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019–2032)

Table 12: Total Prevalent Population of Chronic Lower Back Pain in the United States (2019–2032)

Table 13: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States (2019–2032)

Table 14: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States (2019–2032)

Table 15: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in the US (2019–2032)

Table 16: Total Prevalent Population of Chronic Lower Back Pain in EU-5 (2019–2032)

Table 17: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in EU-5 (2019–2032)

Table 18: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5 (2019–2032)

Table 19: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU5 (2019–2032)

Table 20: Total Prevalent Population of Chronic Lower Back Pain in Japan (2019–2032)

Table 21: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan (2019–2032)

Table 22: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019–2032)

Table 23: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019–2032)

Table 24: Key Cross of Approved Drugs

Table 25: Cymbalta, Clinical Trial Description, 2021

Table 26: Xtampza ER, Clinical Trial Description, 2021

Table 27: Hysingla ER, Clinical Trial Description, 2021

Table 28: Butrans, Clinical Trial Description, 2021

Table 29: Belbuca, Clinical Trial Description, 2021

Table 30: Comparison of emerging drugs under development

Table 31: Brixadi/Buvidal (CAM2038/Buprenorphine Injection Depot), Clinical Trial Description, 2021

Table 32: Semdexa (SP-102), Clinical Trial Description, 2021

Table 33: Rexlemestrocel-L, Clinical Trial Description, 2021

Table 34: AMG0103, Clinical Trial Description, 2021

Table 35: KLS-2031, Clinical Trial Description, 2021

Table 36: ETX-810, Clinical Trial Description, 2021

Table 37: ALLOD-2, Clinical Trial Description, 2021

Table 38: FB3001, Clinical Trial Description, 2021

Table 39: IDCT, Clinical Trial Description, 2021

Table 40: SX600, Clinical Trial Description, 2021

Table 41: STA363, Clinical Trial Description, 2021

Table 42: Clonidine Micropellets, Clinical Trial Description, 2021

Table 43: Tanezumab, Clinical Trial Description 2021

Table 44: LY3556050 Clinical Trial Description, 2021

Table 45: PP353 Clinical Trial Description, 2021

Table 46: BRTX-100, Clinical Trial Description, 2021

Table 47: VER-01, Clinical Trial Description, 2021

Table 48: BM-MSC, Clinical Trial Description, 2021

Table 49: Fasinumab, Clinical Trial Description, 2021

Table 50: Key Market Forecast Assumptions for Brixadi

Table 51: Key Market Forecast Assumptions for Rexlemestrocel-L

Table 52: Key Market Forecast Assumptions for SEMDEXA/SP-102

Table 53: Key Market Forecast Assumptions for Clonidine Micropellets (STX-015)

Table 54: Key Market Forecast Assumptions for Tanezumab

Table 55: Seven Major Market Size of Chronic Lower Back Pain in USD Million (2019–2032)

Table 56: Market Size of Chronic Low Back Pain by therapies in the 7MM, in USD Million (2019–2032)

Table 57: United States Market Size of Chronic Lower Back Pain in USD Million (2019–2032)

Table 58: Market Size of Chronic Low Back Pain by therapies in the US in USD Million (2019–2032)

Table 59: EU-5 Market Size of Chronic Lower Back Pain in USD Million (2019–2032)

Table 60: Market Size of Chronic Low Back Pain by therapies in EU-5 in USD Million (2019–2032)

Table 61: Market Size of Chronic Lower Back Pain in Japan, in USD Million (2019–2032)

Table 62: Market Size of Chronic Low Back Pain by therapies in Japan in USD Million (2019–2032)

List of Figures

Figure 1: Types of Lower Back Pain

Figure 2: Definitions of Chronic Lower Back Pain

Figure 3: Signs and Symptoms of CLBP

Figure 4: Pathophysiological Model for Chronic Low Back Pain Linking Somatic and Behavioral Components

Figure 5: Relationship Describing Therapeutic Inventions and Pathogenic Mechanism

Figure 6: Types of Pain Involved in CLBP mechanism

Figure 7: The Vicious Circle showing the Interaction Of Influencing Factors

Figure 8: Treatment Algorithm for Chronic Low Back Pain

Figure 9: Total Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019–2032)

Figure 10: Diagnosed Prevalent Cases of Chronic Lower Back Pain in the 7MM (2019–2032)

Figure 11: Total Prevalent Population of Chronic Lower Back Pain in the United States (2019–2032)

Figure 12: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in the United States (2019–2032)

Figure 13: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in the United States (2019–2032)

Figure 14: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in the US (2019–2032)

Figure 15: Total Prevalent Population of Chronic Lower Back Pain in EU-5 (2019–2032)

Figure 16: Total Diagnosed Prevalent Population of CLBP in EU-5 (2019–2032)

Figure 17: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5 (2019–2032)

Figure 18: Age - Specific Diagnosed Prevalence of Chronic Lower Back Pain in EU-5 (2019–2032)

Figure 19: Total Prevalent Population of Chronic Lower Back Pain in Japan (2019–2032)

Figure 20: Total Diagnosed Prevalent Population of Chronic Lower Back Pain in Japan (2019–2032)

Figure 21: Gender-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019–2032)

Figure 22: Age-specific Diagnosed Prevalence of Chronic Lower Back Pain in Japan (2019–2032)

Figure 23: Market Size of Chronic Lower Back Pain in the 7MM, USD Millions (2019–2032)

Figure 24: Market Size of Chronic Lower Back Pain by Therapies in the 7MM, USD Millions (2019–2032)

Figure 25: Market Size of Chronic Lower Back Pain in the United States, USD Millions (2019–2032)

Figure 26: Market size of CLBP by therapies in the United States, in USD Million (2019–2032)

Figure 27: Total Market Size of Chronic Lower Back Pain in EU5, USD Millions (2019–2032)

Figure 28: Market Size of Chronic Low Back Pain by therapies in EU-5, in USD Million (2019–2032)

Figure 29: Market Size of Chronic Lower Back Pain in Japan, USD Millions (2019–2032)

Figure 30: Market Size of Chronic Low Back Pain by therapies in Japan, in USD Million (2019–2032)

Figure 31: Market Drivers

Figure 32: Market Barriers

Figure 33: Unmet Needs

Figure 34: SWOT Analysis

Eli Lilly and Company
Collegium Pharmaceutical
Purdue Pharma LP
BioDelivery Sciences International
Camurus
Braeburn Inc.
Scilex Holding
Mesoblast Limited
AnGes MG, Inc.
Kolon Life Science
Eliem Therapeutics
Allodynic Therapeutics
Sollis Therapeutics
Medtronic Spinal and Biologics
Frontier Biotechnologies
DiscGenics Inc.
Pfizer
Persica Pharmaceuticals
BioRestorative Therapies
Vertanical GmbH
Stayble Therapeutics
SpineThera

 

 

Forward to Friend

Need A Quote